Retrospective analysis of survival in muscle-invasive bladder cancer: Impact of pT classification, node status, lymphovascular invasion, and neoadjuvant chemotherapy

Virchows Archiv

Volumn 461, Issue 4, 2012, Pages 467-474

  D'Souza, Amber M ^a   Pohar, Kamal S ^a   Arif, Tahir ^a   Geyer, Susan ^a   Zynger, Debra L ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Bladder cancer; Lymph node; Neoadjuvant; Stage; Survival

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINCRISTINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER INVASION; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CYSTECTOMY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; COMBINED MODALITY THERAPY; CYSTECTOMY; DRUG THERAPY; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUSCLE, SMOOTH; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84867395809     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1249-4     Document Type: Article

References (34)

1. American Cancer Society (2010) Cancer Facts and Figures 2010. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-026238.pdf, Accessed 3 January 2012
2. National Cancer Institute (2010). Bladder Cancer Information. http://www.cancer.gov/cancertopics/types/bladder. Accessed 3 January 2012
3. Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859-866 (Pubitemid 37025405)
4. Kaufman DS, Shipley WU, Feldman AS (2009) Bladder cancer. Lancet 374:239-249
5. Logothetis CJ, Dexeus FH, Finn L et al (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050-1055 (Pubitemid 20200193)
6. Von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077
7. Canter D, Long C, Kutikov A, Plimack E et al (2011) Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int 107:58-62
8. Edge SB, Byrd DR, Comptom CC (2010) American Joint Committee on Cancer. AJCC Cancer Staging Manual, Seventh Edition. Springer, New York, pp 497-502
9. Fedeli U, Fedewa SA, Ward EM (2011) Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 200. to 2007. J Urol 185:72-78
10. Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. J Clin Oncol 19:666-675 (Pubitemid 32120143)
11. Madersbacher S, Hochreiter W, Burkhard F et al (2003) Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 21:690-696 (Pubitemid 46621904)
12. Weight CJ, Garcia JA, Hansel DE et al (2009) Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Cancer 115:792-799
13. Manoharan M, Katkoori D, Kishore TA et al (2009) Outcome after radical cystectomy in patients with clinical T2 bladder cancer in whom neoadjuvant chemotherapy has failed. BJU Int 104:1646-1649
14. Pollack A, Zagars GK, Cole CJ et al (1995) The relationship of local control to distant metastasis in muscle invasive bladder cancer. J Urol 154:2059-2063
15. Honma I, Masumori N, Sato E et al (2004) Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors. Urology 64:744-748 (Pubitemid 39446055)
16. Tilki D, Svatek RS, Karakiewicz PI et al (2010) pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. J Urol 184:470-474
17. Sonpavde G, Khan MM, Svatek RS et al (2011) Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol 185:1216-1221
18. Yu RJ, Stein JP, Cai J et al (2006) Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol 176:493-8
19. Boudreaux KJ Jr, Clark PE, Lowrance WT et al (2009) Comparison of American Joint Committee on Cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol 181:540-545
20. Tilki D, Svatek RS, Novara G et al (2010) Stage pT0 at radical cystectomy confers improved survival: an international study of 4, 430 patients. J Urol 184:888-894
21. Amling CL, Thrasher JB, Frazier HA et al (1994) Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 151:31-35
22. Ghoneim MA, El-Mekresh MM, Mokhtar AA et al (2000) A predictive model of survival after radical cystectomy for carcinoma of the bladder. BJU Int 85:811-816 (Pubitemid 30242783)
23. Abdel-Latif M, Abol-Enein H, El-Baz M et al (2004) Nodal involvement in bladder cancer cases treated with radical cystectomy: incidence and prognosis. J Urol 172:85-89 (Pubitemid 41615044)
24. Lotan Y, Gupta A, Shariat SF et al (2005) Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23:6533-6539 (Pubitemid 46190245)
25. Quek ML, Stein JP, Nichols PW et al (2005) Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol 174:103-106 (Pubitemid 40825683)
26. Shariat SF, Svatek RS, Tilki D et al (2010) International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 105:1402-1412
27. Yang XJ, Lecksell K, Eptsein JI (1999) Can immunohistochemistry enhance the detection of micrometasasis in pelvic lymph nodes from patients with high-grade urothelial carcinoma of the bladder? Am J Clin Pathol 112:649-653 (Pubitemid 30214755)
28. International Collaboration of Trialists (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354:533-540
29. Sonpavde G, Goldman BH, Speights VO et al (2009) Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 115:4104-4019
30. Sherif A, Rintala E, Mestad O et al (2002) Neoadjuvant cisplatinmethotrexate chemotherapy for invasive bladder cancer-Nordic cystectomy trial 2. Scand J Urol Nephrol 36:419-425 (Pubitemid 36169500)
31. Advanced Bladder Cancer Meta-analysis Collaboration (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361:1927-1934
32. Sherif A, Holmberg L, Rintala E et al (2004) Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 45:297-303 (Pubitemid 38221402)
33. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48:202-205
34. International Collaboration of Trialists (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171-2177